
Updated
New research presented at Neuroscience 2026 indicates that biological sex, genetics and menopause may shape Alzheimer's risk, treatment responses and chronic pain such as fibromyalgia. ScienceDaily reported four studies presented at Neuroscience 2026, the Society for Neuroscience's annual meeting, on how sex and genetics may affect neurological disorders. Alzheimer's, an incurable disorder that progressively damages memory, affects an estimated 35 to 40 million people worldwide, according to the World Health Organization, while fibromyalgia, marked by persistent pain and fatigue, affects 2 to 4 percent of the global population. Mateja Perović of the University of Toronto found that people with Alzheimer's genetic risk factors responded differently to menopause hormone therapy, with effects varying by hormone combination. Stephanie M. Perez of the University of Texas Health Science Center at San Antonio found that in menopausal rodents carrying Alzheimer's genetic risk factors, memory brain circuits became particularly vulnerable. In a mouse fibromyalgia model, Yasmin Sahlloul of the University of Cincinnati found that females showed heightened touch sensitivity and stronger immune activation than males. Nurcan Kilic of the University of North Dakota found that chronic gut inflammation affected brain function and Alzheimer's-related changes differently in male and female mice. The findings could open the door to more personalized treatments for neurological disorders.